Skip to main contentSkip to footer
ORYL Photonics homepage

SPR ROI Calculator

Calculate your SPR savings with ORYL F1

How much does running SPR without solubility triage cost you per year? Eleven inputs, three strategies (pre-filter, SPR + resume, SPR + restart), your numbers.

Why it works

What pre-analytical screening prevents

Economical

Eliminate wasted SPR runs

Aggregators and insoluble compounds generate unreliable binding data, yet consume the same instrument time and reagent cost as clean compounds. Screen them out before they reach the SPR.

Robust

Protect chips and fluidics

Particulates and aggregated material damage sensor chip surfaces and clog SPR fluidic systems. Pre-filtering problem compounds significantly reduces catastrophic failures and unplanned service events.

Fast

No mid-campaign restarts

A single catastrophic chip failure can invalidate hours of binding kinetics work and delay campaign decisions. Solubility and aggregation triage before SPR removes the source of these failures entirely.

Your lab parameters

Adjust the sliders to reflect your throughput and costs.

Compounds per campaign 1,000
Campaigns per year 10
Problem compound rate 10%
Aggregators, precipitators, and non-specific binders in your hit list
% of those that are catastrophic 3%
Compounds that kill the chip mid-run and require surface re-prep
SPR cost per compound $50
Sensor chip cost $600
Additional cost parameters
Compounds per chip (planned lifecycle) 250
Compounds run per chip under normal, uninterrupted conditions
Solubility assay cost per compound $5
Re-prep cost per chip failure $2,000
Labour and protein cost to re-immobilise after a catastrophic failure
Microfluidics service events / year 2
Cost per microfluidics repair $5,000

Solubility assay sensitivity is 100%. If your assay catches only X% of problem compounds, discount the savings by that fraction.

Microfluidics damage is partly driven by problem compounds. The model assumes pre-filtering eliminates ~50% of fluidics-damage risk. The residual reflects wear, contamination, and operator error.

Catastrophic failures waste an average of half a chip. In the conservative scenario only the pre-failure batch is re-run; in the aggressive scenario the full chip batch is invalidated.

Instrument downtime, project delays, and protein supply are not priced. These factors typically strengthen the savings case further.

Estimated annual savings with ORYL F1
vs. no pre-screening
re-run only the failed batch
—
per year
vs. no pre-screening
discard & restart the full chip batch
—
per year
Compared to running all compounds on SPR without solubility pre-screening. Planning estimate — validate with your historical data before use in business cases.
With ORYL F1 Solubility pre-screening
—
Triage first. SPR only on clean, soluble compounds.
Solubility assays (all compounds)—
SPR runs (clean compounds only)—
Planned chip consumption—
Microfluidics (50% residual)—
Annual total—
No pre-screening Re-run only the failed batch
—
All compounds go to SPR. On chip failure, only the pre-failure half-batch is re-run.
SPR runs (all compounds)—
Wasted SPR (½ chip per failure)—
Chip consumption + re-prep—
Microfluidics (full rate)—
Annual total—
No pre-screening Discard & restart the full chip batch
—
All compounds go to SPR. On chip failure, the entire chip batch is invalidated and restarted.
SPR runs (all compounds)—
Wasted SPR (full chip per failure)—
Chip consumption + re-prep—
Microfluidics (full rate)—
Annual total—

Ready to de-risk early?

Our application scientists can provide a personalised ROI report based on your instrument setup and campaign throughput.

Request a Demo
Request a Measurement Service